- Conditions
- Hereditary Angioedema
- Interventions
- Lanadelumab
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 11
- States / cities
- Santa Monica, California • Walnut Creek, California • Centennial, Colorado + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–90
of 90
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- DX-2930 - 300mg/2wk, DX-2930 - 300mg/4wk, DX-2930 - 150mg/4wk, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 28 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- CINRYZE with rHuPH20
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 14 more
- Conditions
- Hereditary Angioedema
- Interventions
- KVD900 600 mg, KVD900 300 mg
- Drug
- Lead sponsor
- KalVista Pharmaceuticals, Ltd.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • San Diego, California + 16 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- CSL312
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Litchfield Park, Arizona • Scottsdale, Arizona • Orange, California + 4 more
- Conditions
- Acute Hereditary Angio Edema
- Interventions
- OCTA-C1-INH, Placebo
- Drug · Other
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Centennial, Colorado • Farmington Hills, Michigan • Toledo, Ohio
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- CINRYZE
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 8
- States / cities
- Colorado Springs, Colorado • Tampa, Florida • Chevy Chase, Maryland + 5 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- Not listed
- Lead sponsor
- Shire
- Industry
- Eligibility
- Not listed
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 20 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- C1 esterase inhibitor [human] liquid, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 13 more
- Conditions
- Hereditary Angioedema
- Interventions
- Factor XIIa antagonist monoclonal antibody, Placebo
- Biological · Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 7
- States / cities
- Orange, California • Walnut Creek, California • Centennial, Colorado + 4 more
- Conditions
- Hereditary Angioedema Types I and II
- Interventions
- C1-esterase inhibitor
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 9 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- Deucrictibant, Placebo
- Drug
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • San Diego, California • Santa Monica, California + 3 more
- Conditions
- Hereditary Angioedema, HAE, Prophylaxis
- Interventions
- BCX7353
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 387 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 39 more
- Conditions
- Hereditary Angioedema, HAE
- Interventions
- Dose 1 of BMN 331, Dose 2 of BMN 331, Dose 3 of BMN 331, Dose 4 of BMN 331, Dose 5 of BMN 331, Dose 6 of BMN 331, Dose 7 of BMN 331
- Genetic
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 10 more
- Conditions
- Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
- Interventions
- ADX-324 Dose Level 1, ADX-324 Dose Level 2
- Drug
- Lead sponsor
- ADARx Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 15
- States / cities
- Litchfield Park, Arizona • Little Rock, Arkansas • San Diego, California + 12 more
- Conditions
- Hereditary Angioedema (HAE), Angioedema
- Interventions
- Lanadelumab 150 mg, Lanadelumab 300 mg
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 2 Years and older
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 10 more
- Conditions
- Ebola Virus Disease, Marburg Virus Disease
- Interventions
- cAd3-Marburg, cAd3-EBO-S
- Biological
- Lead sponsor
- Albert B. Sabin Vaccine Institute
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Hereditary Angioedema
- Interventions
- C1 Esterase Inhibitor, Placebo
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 17
- States / cities
- Granada Hills, California • Weston, Florida • Atlanta, Georgia + 14 more